Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | VAL-083 |
Synonyms | |
Therapy Description |
Dianhydrogalactitol (VAL-083) is a DNA cross-linking agent which has shown anti-tumor activities in clinical settings (Journal of Clinical Oncology 36, no. 15_suppl., PMID: 6784907). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
VAL-083 | Dianhydrogalactitol|VAL083|VAL 083 | Dianhydrogalactitol (VAL-083) is a DNA cross-linking agent which has shown anti-tumor activities in clinical settings (Journal of Clinical Oncology 36, no. 15_suppl., PMID: 6784907). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT01478178 | Phase Ib/II | VAL-083 | Safety Study of VAL-083 in Patients With Recurrent Malignant Glioma or Progressive Secondary Brain Tumor | Completed | USA | 0 |
NCT02717962 | Phase II | VAL-083 | Study of VAL-083 in Patients With MGMT Unmethylated, Bevacizumab-naive Recurrent Glioblastoma | Active, not recruiting | USA | 0 |